Ishita Drugs & Industries Ratios

Ishita Drugs & Industries Ltd Ratios

The Ishita Drugs & Industries Ltd Ratios page provides a complete fundamental analysis of Ishita Drugs & Industries Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Ishita Drugs & Industries Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Ishita Drugs & Industries Ltd (NSE: , BSE: 524400) is currently trading at ₹70.97, with a market capitalization of ₹212.22M. As a major player in the Health technology sector and Pharmaceuticals: other industry, Ishita Drugs & Industries Ltd remains a key stock for fundamental analysis using Ishita Drugs & Industries Ltd Ratios.

Ishita Drugs & Industries Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Ishita Drugs & Industries Ltd P/E ratio currently stands at 27.05, making it one of the most tracked metrics in Ishita Drugs & Industries Ltd Ratios.

Historically, the Ishita Drugs & Industries Ltd P/E ratio has shown strong fluctuations:

• 2024: 27.05
• 2023: 26.20
• 2022: 25.59
• 2021: 15.36
• 2020: 10.81

The rising Ishita Drugs & Industries Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Ishita Drugs & Industries Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.18.

Historical P/B trend:

• 2024: 2.18
• 2023: 1.98
• 2022: 1.61
• 2021: 1.44

Ishita Drugs & Industries Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Ishita Drugs & Industries Ltd P/S ratio currently stands at 1.57, an important part of Ishita Drugs & Industries Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.57
• 2023: 1.29
• 2022: 1.22
• 2021: 0.88

The rising Ishita Drugs & Industries Ltd P/S ratio indicates improved revenue valuation by investors.

Ishita Drugs & Industries Ltd Price to Cash Flow Ratio (P/CF)

The Ishita Drugs & Industries Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Ishita Drugs & Industries Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 8.48
• 2022: 0
• 2021: 3.92
• 2020: 0

The declining Ishita Drugs & Industries Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Ishita Drugs & Industries Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Ishita Drugs & Industries Ltd EV currently stands at ₹190.4M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 190.4M
• 2023: 117.35M
• 2022: 91.88M
• 2021: 38.9M

Ishita Drugs & Industries Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Ishita Drugs & Industries Ltd EV/EBITDA ratio is currently 19.01, a key metric in Ishita Drugs & Industries Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 19.01
• 2023: 12.92
• 2022: 12.06
• 2021: 3.56

Higher Ishita Drugs & Industries Ltd EV/EBITDA suggests premium valuation.

Ishita Drugs & Industries Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Ishita Drugs & Industries Ltd D/E ratio is currently 0.36, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.36
• 2023: 0
• 2022: 0.10
• 2021: 0

Ishita Drugs & Industries Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Ishita Drugs & Industries Ltd ROE currently stands at 8.38%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 8.38
• 2023: 7.84
• 2022: 6.50
• 2021: 9.82

Declining ROE indicates pressure on profitability.

Ishita Drugs & Industries Ltd Ratios Analysis Summary

The Ishita Drugs & Industries Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Ishita Drugs & Industries Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Ishita Drugs & Industries Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.